Cancer Research Technology
Log in Register
Menu

pJEK1 Alpha-Synuclein Vector

Invented by Dr Fiona Benson from Lancaster University
Invented at Lancaster University

Info

Catalogue Number 152046
Antigen/Gene or Protein Targets Alpha-synuclein
Relevance Alpha-synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Research Area Neurobiology
Notes pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag.

2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.

Europe PMC ID: 15180968


Add a reference

References: 2 entries

El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.


Add a reference